CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically…
VANCOUVER, Washington - (BUSINESS WIRE) - CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Firm"), a late-stage biotechnology firm creating Leronlimab, a CCR5 antagonist with potential for a number of therapeutic indications,…